Want to see IDXG full AI Analyst Report?
Top Page
Interpace Diagnostics Group
(OTC:IDXG)
Select Model
Select Model
Rating:69Neutral
Price Target:
$2.00
▲(36.99% Upside)
Action:Downgraded
Date:08/21/26
The score is primarily supported by improved financial health (profitability turnaround, low leverage, and positive cash flow). Offsetting this are declining revenue and weakening cash conversion in TTM, while technicals are largely neutral. Valuation appears very low based on P/E, but the potential reverse-split authorization adds a modest risk factor.
Positive Factors
Profitability Turnaround
The shift to sustained operating and net profitability strengthens internal funding capacity and demonstrates improved economics versus prior loss-making periods, although future durability depends on maintaining results as revenue declines.
Negative Factors
Declining Revenue
Persistent revenue contraction threatens operating leverage, test-volume growth, and the ability to sustain recent profitability. It also suggests that improved earnings may not represent a durable expansion of the core business.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability Turnaround
The shift to sustained operating and net profitability strengthens internal funding capacity and demonstrates improved economics versus prior loss-making periods, although future durability depends on maintaining results as revenue declines.
Read all positive factors
Interpace Diagnostics Group (IDXG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$43.49M
Dividend YieldN/A
Average Volume (3M)11.58K
Price to Earnings (P/E)0.3
Beta (1Y)1.67
Revenue Growth-20.48%
EPS Growth537.50%
CountryUS
Employees102
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)5.38
Shares Outstanding27,700,905
10 Day Avg. Volume15,402
30 Day Avg. Volume11,583
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.14
P/FCF Ratio0.99
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Interpace Diagnostics Group Business Overview & Revenue Model
Company Description
Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive geno...
How the Company Makes Money
IDXG primarily makes money by performing diagnostic testing services and recognizing revenue when it delivers test results for patient specimens processed through its laboratory operations. Key revenue streams generally include (1) reimbursement f...
Interpace Diagnostics Group Financial Statement Overview
Summary
Income Statement
70
Positive
Balance Sheet
78
Positive
Cash Flow
66
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 36.14M | 38.73M | 46.93M | 40.21M | 31.84M | 41.31M |
| Gross Profit | 23.04M | 24.13M | 29.93M | 23.90M | 18.23M | 17.95M |
| EBITDA | 4.92M | 4.76M | 8.36M | 3.84M | -2.27M | -1.33M |
| Net Income | 24.45M | 24.57M | 6.70M | 802.00K | -5.87M | -14.75M |
Balance Sheet | ||||||
| Total Assets | 34.55M | 33.84M | 14.79M | 13.02M | 15.98M | 38.43M |
| Cash, Cash Equivalents and Short-Term Investments | 2.69M | 2.50M | 1.46M | 3.50M | 4.83M | 3.31M |
| Total Debt | 974.00K | 1.18M | 5.86M | 11.19M | 16.09M | 13.72M |
| Total Liabilities | 11.30M | 11.47M | 17.01M | 28.16M | 79.05M | 80.84M |
| Stockholders Equity | 23.24M | 22.36M | -2.22M | -15.14M | -63.07M | -42.42M |
Cash Flow | ||||||
| Free Cash Flow | 4.10M | 5.47M | 3.77M | 3.32M | -8.01M | -9.07M |
| Operating Cash Flow | 4.46M | 5.83M | 4.65M | 3.79M | -7.69M | -8.72M |
| Investing Cash Flow | -353.00K | -356.00K | -876.00K | -87.00K | 6.21M | -315.00K |
| Financing Cash Flow | -1.92M | -4.43M | -5.81M | -5.03M | 3.00M | 8.98M |
Interpace Diagnostics Group Technical Analysis
Negative
1.46
Price Trends
1.60
Positive
1.77
Negative
1.59
Positive
Market Momentum
0.01
Negative
50.05
Neutral
22.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDXG, the sentiment is Negative. The current price of 1.46 is below the 20-day moving average (MA) of 1.59, below the 50-day MA of 1.60, and below the 200-day MA of 1.59, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 50.05 is Neutral, neither overbought nor oversold. The STOCH value of 22.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IDXG.
Interpace Diagnostics Group Risk Analysis
Interpace Diagnostics Group disclosed 63 risk factors in its most recent earnings report. Interpace Diagnostics Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Interpace Diagnostics Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $3.39B | 29.02 | 8.64% | ― | 17.28% | 323.64% | |
71 Outperform | $987.36M | -49.93 | -4.15% | ― | 3.18% | -100.37% | |
69 Neutral | $43.49M | 0.30 | -446.40% | ― | -20.48% | 537.50% | |
60 Neutral | $2.14B | -8.33 | -6.31% | ― | 11.19% | 50.58% | |
60 Neutral | $21.92B | -48.10 | 211.46% | ― | 42.74% | -4.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
38 Underperform | $305.12M | -2.70 | -32.59% | ― | -3.16% | 72.02% |
* Healthcare Sector Average
IDXG
Interpace Diagnostics Group
1.61
0.73
82.95%
MYGN
Myriad Genetics
3.22
-2.61
-44.77%
VCYT
Veracyte
41.79
12.36
42.00%
NEO
NeoGenomics
16.53
10.35
167.48%
GH
Guardant Health
167.88
106.60
173.96%
CSTL
Castle Biosciences
32.93
12.96
64.90%
Interpace Diagnostics Group Corporate Events
Business Operations and StrategyShareholder MeetingsStock Split
Interpace Diagnostics Shareholders Approve Governance and Equity Plans
Positive
Aug 21, 2026
At its August 20, 2026 annual meeting, Interpace Diagnostics Group shareholders approved an amended and restated certificate of incorporation and granted the board authority to implement a reverse stock split within a one-for-two to one-for-ten ra...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.